Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice

• Published in: Current controlled trials in cardiovascular medicine Vol. 10; no. 1; p. 113
• Main Authors: Pencille, Laurie J, Campbell, Megan E, Van Houten, Holly K, Shah, Nilay D, Mullan, Rebecca J, Swiglo, Brian A, Breslin, Maggie, Kesman, Rebecca L, Tulledge-Scheitel, Sidna M, Jaeger, Thomas M, Johnson, Ruth E, Bartel, Gregory A, Wermers, Robert A, Melton, 3rd, L Joseph, Montori, Victor M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10-12-2009; BioMed Central; BMC
• Subjects: Bisphosphonates; Care and treatment; Clinical trials; Complications and side effects; Decision Making; Diabetes; Diagnosis; Diphosphonates; Diphosphonates - therapeutic use; Dosage and administration; Estimates; Female; Follow-Up Studies; Fractures; Fractures, Bone - epidemiology; Fractures, Bone - prevention & control; Humans; Intervention; Management; Middle Aged; Osteoporosis; Osteoporosis - drug therapy; Osteoporosis - epidemiology; Patients; Pilot Projects; Prevention; Primary care; Primary Health Care - methods; Risk Factors; Study protocol; United States; United States > US; Minnesota
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/1745-6215-10-113

Bisphosphonates can reduce fracture risk in patients with osteoporosis, but many at-risk patients do not start or adhere to these medications. The aims of this study are to: (1) preliminarily evaluate the effect of an individualized 10-year osteoporotic fracture risk calculator and decision aid (OSTEOPOROSIS CHOICE) for postmenopausal women at risk for osteoporotic fractures; and (2) assess the feasibility and validity (i.e., absence of contamination) of patient-level randomization (vs. cluster randomization) in pilot trials of decision aid efficacy.
This is a protocol for a parallel, 2-arm, randomized trial to compare an intervention group receiving OSTEOPOROSIS CHOICE to a control group receiving usual primary care. Postmenopausal women with bone mineral density T-scores of <-1.0, not receiving bisphosphonate therapy, and receiving care at participating primary care practices in and around Rochester, Minnesota, USA will be eligible to participate in the trial. We will measure the effect of OSTEOPOROSIS CHOICE on five outcomes: (a) patient knowledge regarding osteoporosis risk factors and treatment; (b) quality of the decision-making process for both the patient and clinician; (c) patient and clinician acceptability and satisfaction with the decision aid; (d) rate of bisphosphonate use and adherence, and (e) trial processes (e.g., ability to recruit participants, collect patient outcomes). To capture these outcomes, we will use patient and clinician surveys following each visit and video recordings of the clinical encounters. These video recordings will also allow us to determine the extent to which clinicians previously exposed to the decision aid were able to recreate elements of the decision aid with control patients (i.e., contamination). Pharmacy prescription profiles and follow-up phone interviews will assess medication start and adherence at 6 months.
This pilot trial will provide evidence of feasibility, validity of patient randomization, and preliminary efficacy of a novel approach--decision aids--to improving medication adherence for postmenopausal women at risk of osteoporotic fractures. The results will inform the design of a larger trial that could provide more precise estimates of the efficacy of the decision aid.
Clinical Trials.gov Identifier: NCT00578981.